SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
[X] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act
of 1934 for the quarterly period ended September 30, 2005.
[ ] Transition report under Section 13 or 15(d) of the Securities Exchange Act
of 1934 for the transition period from ______________ to ______________
Commission file number: 000-32767
AJ & J PHARMA CORPORATION
--------------------------------------
(Exact name of small business issuer as specified in its charter)
NEVADA 86-1024812
- --------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
10135 E Via Linda Road, Suite D-224A, Scottsdale, AZ 85260
----------------------------------------------------------
(Address of principal executive office) (Zip Code)
602-821-6492
---------------------
(Issuer's telephone number)
Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes XX No
---- ----
The number of outstanding shares of the issuer's common stock, $0.001 par value,
as of September 30, 2005 was 1,000,000.
1
AJ & J PHARMA CORPORATION
(A DEVELOPMENT STAGE COMPANY)
TABLE OF CONTENTS
Part I Financial Information Page
Item 1.Financial Statements:
Condensed Balance Sheets
September 30, 2005 (unaudited) and December 31, 2004 ................. 3
Unaudited Condensed Statements of Operations for the three
and nine months ended September 30, 2005 and 2004, and
cumulative from inception on July 16, 1998 through September
30, 2005............................................................. 4
Unaudited Condensed Statements of Cash Flows for the three
and nine months ended September 30, 2005 and 2004, and
cumulative from inception on July 16, 1998 through September
30, 2005 ............................................................. 5
Statement of Stockholders' equity for the period from
July 16,1998 to September 30, 2005 (unaudited) ....................... 6
Notes to Financial Statements (unaudited)............................. 7
Item 2. Plan of operation..................................................... 7
Part II Other Information
Item 1. Legal Proceedings .................................................... 7
Item 2. Changes in Securities ................................................ 7
Item 6. Exhibits and Reports on Form 8-K ..................................... 7
Signatures ................................................................... 8
Certifications ............................................................... 9
2
AJ & J PHARMA CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONDENSED BALANCE SHEETS
September 30, December 31,
2005 2004
------------ ------------
(unaudited)
ASSETS
------
ASSETS $ -- $ --
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
----------------------------------------------
CURRENT LIABILITIES
Accounts payable, Officers $ 31,700 $ 26,538
------------ ------------
Total Current Liabilities 31,700 26,538
------------ ------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value $.001, 25,000,000
shares authorized, 1,000,000 issued and
outstanding 1,000 1,000
Paid in capital 1,800 1,800
(Deficit) accumulated during the development stage (34,500) (29,338)
------------ ------------
Total Stockholders' Equity (Deficit) (31,700) (26,538)
------------ ------------
$ -- $ --
============ ============
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
3
AJ & J PHARMA CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
Cumulative
from
July 16,
1998
Three Months Ended Nine Months Ended (Inception)
September 30, September to
-------------------------- -------------------------- September 30,
2005 2004 2005 2004 2005
----------- ----------- ----------- ----------- -------------
REVENUES $ -- $ -- $ -- $ -- $ --
----------- ----------- ----------- ----------- -------------
EXPENSES
General and administrative 1,416 1,416 5,162 5,134 34,500
----------- ----------- ----------- ----------- -------------
Total expenses 1,416 1,416 5,162 5,134 34,500
----------- ----------- ----------- ----------- -------------
NET (LOSS) $ (1,416) $ (1,416) $ (5,162) $ (5,134) $ (34,500)
=========== =========== =========== =========== =============
NET (LOSS) PER SHARE * * * *
=========== =========== =========== ===========
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 1,000,000 1,000,000 1,000,000 1,000,000
=========== =========== =========== ===========
* less than $.01 per share
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
4
AJ & J PHARMA CORPORATION
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Cumulative
from
July 16,
1998
Nine Months Ended (Inception)
September 30, to
---------------------------- September 30,
2005 2004 2005
------------ ------------ ------------
OPERATING ACTIVITIES
Net (loss) from operations $ (5,162) $ (5,134) $ (34,500)
------------ ------------ ------------
NET CASH (USED BY) OPERATING ACTIVITIES (5,162) (5,134) (34,500)
------------ ------------ ------------
FINANCING ACTIVITIES
Shareholder advances 5,162 5,134 31,700
Proceeds from sale of common stock 2,800
------------ ------------ ------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 5,162 5,134 34,500
------------ ------------ ------------
NET INCREASE IN CASH -- -- --
CASH, BEGINNING OF PERIOD --
------------ ------------ ------------
CASH, END OF PERIOD $ -- $ -- $ --
============ ============ ============
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
5
AJ & J PHARMA CORPORATION
( a Development Stage Company)
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(Deficit)
Accumulated
Common Stock During the
------------------------ Paid-in Development
Shares Amount Capital Stage Total
---------- ---------- ---------- ---------- ----------
Balances, at inception -- $ -- $ -- $ -- $ --
July 16, 1998:
Proceeds from sale of common
stock at $.01 per share 200,000 200 1,800 2,000
Proceeds from sale of common
stock at par value $.001 800,000 800 800
Net (loss) for the period (2,385) (2,385)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 1998 1,000,000 1,000 1,800 (2,385) 415
Net (loss) for the year (2,985) (2,985)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 1999 1,000,000 1,000 1,800 (5,370) (2,570)
Net (loss) for the year (2,985) (2,985)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 2000 1,000,000 1,000 1,800 (8,355) (5,555)
Net (loss) for the year (5,685) (5,685)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 2001 1,000,000 1,000 1,800 (14,040) (11,240)
Net (loss) for the year (4,335) (4,335)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 2002 1,000,000 1,000 1,800 (18,375) (15,575)
Net (loss) for the year (4,358) (4,358)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 2003 1,000,000 $ 1,000 $ 1,800 $ (22,733) $ (19,933)
Net (loss) for the year (6,605) (6,605)
---------- ---------- ---------- ---------- ----------
Balances, December 31, 2004 1,000,000 $ 1,000 $ 1,800 $ (29,338) $ (26,538)
(unaudited)
Net (loss) for nine months (5,162) (5,162)
---------- ---------- ---------- ---------- ----------
Balances,
September 30, 2005 (unaudited) 1,000,000 $ 1,000 $ 1,800 $ (34,500) $ (31,700)
========== ========== ========== ========== ==========
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
6
AJ & J PHARMA CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(unaudited)
Note 1. BASIS OF PRESENTATION
In the opinion of management, the accompanying unaudited condensed financial
statements have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form
10-QSB. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting of normal
recurring accruals) considered necessary for a fair presentation of the
Company's financial position as of September 30, 2005 and the results of its
operations for the three and nine months ended September 30, 2005, and cash
flows for the nine months ended September 30, 2005 have been made. Operating
results for the nine months ended September 30, 2005 are not necessarily
indicative of the results that may be expected for the year ended December 31,
2005.
These condensed financial statements should be read in conjunction with the
financial statements and notes thereto contained in the Company's Form 10-KSB
for the year ended December 31, 2004.
ITEM 2. PLAN OF OPERATION
For the near term, the Company continues to seek merger and/or acquisition
candidates. It has had no operations since inception and is financially
dependent on its shareholders, who have financed its existence to date.
Management of the Company believes that its shareholders will continue to
provide the finances the Company requires, without the need to raise additional
capital.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 2. Changes in Securities
None
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
31.1 Certificate of CEO as Required by Rule 13a-14(a)/15d-14
31.2 Certificate of CFO as Required by Rule 13a-14(a)/15d-14
32.1 Certificate of CEO as Required by Rule Rule 13a-14(b) and Rule
15d-14(b) (17 CFR 240.15d-14(b)) and Section 1350 of Chapter 63 of
Title 18 of the United States Code
32.1 Certificate of CFO as Required by Rule Rule 13a-14(b) and Rule
15d-14(b) (17 CFR 240.15d-14(b)) and Section 1350 of Chapter 63 of
Title 18 of the United States Code
(b) Reports on Form 8-K
None
7
SIGNATURE
In accordance with Section 12 of the Securities Exchange Act of 1934, the
registrant caused this registration statement to be signed on its behalf by the
undersigned, thereto duly authorized.
AJ & J PHARMA CORPORATION
(Registrant)
Date: November 10, 2005
By:/s/Kevin Ericksteen
- ----------------------------
Kevin Ericksteen
President and Director
8